Consistent with our prior communications, our expectation remains that regulatory submissions could occur after we have the final overall survival data in 2018. At the American Academy of Dermatology Meeting, we presented Phase 3 data showing that patients with moderate-to-severe plaque psoriasis treated with ixekizumab, or Taltz, demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara